Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: SK potassium channel inhibitors - Acesion Pharma

Drug Profile

Research programme: SK potassium channel inhibitors - Acesion Pharma

Alternative Names: NS 309; NS 4591; NS 8593

Latest Information Update: 07 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroSearch
  • Developer Acesion Pharma; NeuroSearch
  • Class Indoles; Oximes; Small molecules
  • Mechanism of Action Intermediate conductance calcium activated potassium channel modulators; Small conductance calcium activated potassium channel modulators; Small conductance calcium-activated potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Atrial fibrillation
  • Discontinued Chronic obstructive pulmonary disease; Epilepsy; Overactive bladder

Most Recent Events

  • 08 Feb 2018 Acesion Pharma plans a phase I trial of AP 30663 for Atrial fibrillation (In healthy volunteers) in Netherlands in March 2018
  • 01 Oct 2016 Preclinical development is ongoing Denmark
  • 02 Dec 2013 Preclinical development is ongoing in Denmark
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top